Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity
Type 2 Diabetes

Interventions

DRUG: Cagrilintide
DRUG: Placebo (matched to Cagrilintide)

Sponsor

Novo Nordisk A/S